Dr Kin Cheng
Kin has several years’ experience in clinical development strategy and competitive intelligence in immuno-oncology.
He has conducted secondary research on unmet medical need, epidemiology, and technology assessments to help inform the strategic management of a pipeline of CAR-T therapies. He has also monitored the competitive landscape and provided insight into current and future market trends, particularly in oncology.
Kin was a research scientist for several years and holds a PhD in Immunology from the National University of Singapore.
Outside of work, Kin enjoys hiking, skiing, and exploring rural Japan.